Ketalar (Ketamine)

Ketamine blocks the NMDA receptor, a key excitatory pathway in the central nervous system. This inhibition disrupts pain transmission and produces a dissociative anesthetic state, while also stimulating opioid receptors and increasing sympathetic tone, contributing to its analgesic and cardiovascular effects.

The dose of Ketalar is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended procedure. Healthcare providers calculate the appropriate amount and route of administration according to established medical guidelines.

The safety of ketamine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ketalar (ketamine) differs from traditional inhalational or opioid anesthetics by providing dissociative anesthesia without significant respiratory depression. It also maintains airway reflexes and stimulates sympathetic output, which can be advantageous in trauma or hemodynamically unstable patients compared with agents that cause hypotension.

Ketalar should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Ensure the container is tightly sealed to maintain sterility until use.

Ketalar is administered by a qualified professional via intramuscular or intravenous injection. The route, rate, and total dose are individualized based on the procedure, patient characteristics, and clinical response, with continuous monitoring of vital signs throughout the administration.

Serious risks include respiratory depression, laryngospasm, severe hypertension, emergence delirium, hallucinations, seizures, and rare allergic reactions. Continuous monitoring of airway, breathing, and circulation is essential to detect and manage these events promptly.

Ketalar is contraindicated in patients with known hypersensitivity to ketamine or its excipients. Caution is advised for individuals with severe cardiovascular disease, uncontrolled hypertension, schizophrenia, or other severe psychiatric disorders, and it should be avoided in patients where airway protection cannot be guaranteed.